Ratings Aarti Drugs Limited

Equities

AARTIDRUGS

INE767A01016

Delayed Bombay S.E. Other stock markets 04:28:25 2024-05-06 am EDT			5-day change	1st Jan Change
493.4 ^INR	-1.60%		-2.88%	+0.88%

07:30am	Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024
May. 03	Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

With a 2024 P/E ratio at 26.81 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
AARTI DRUGS LIMITED	+0.88%	553M	D+
ELI LILLY AND COMPANY	+26.08%	662B	C+
NOVO NORDISK A/S	+22.66%	546B	B
JOHNSON & JOHNSON	-4.77%	359B	C+
MERCK & CO., INC.	+16.97%	323B	B-
ABBVIE INC.	+5.69%	289B	C+
ASTRAZENECA PLC	+13.68%	234B	B+
NOVARTIS AG	+4.22%	198B	B-
ROCHE HOLDING AG	-10.88%	194B	A+
AMGEN INC.	+8.08%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes